The effect of REACH implementation on genotoxicity and carcinogenicity testing Jan van Benthem

Size: px
Start display at page:

Download "The effect of REACH implementation on genotoxicity and carcinogenicity testing Jan van Benthem"

Transcription

1 The effect of REACH implementation on genotoxicity and carcinogenicity testing Jan van Benthem National Institute for Public Health and the Environment Laboratory for Health Protection Research Bilthoven The Netherlands Facts: This talk is my personal view and may deviate from the official opinion of the RIVM or Dutch government I am not a regulator

2 REACH Registration, Evaluation, Authorisation and Restriction of CHemicals Registratie, Evaluatie en Autorisatie van CHemische stoffen Registrement, Evaluation et Autorisation des produits CHimiques Aims: Safety assessment for new and existing chemicals For existing chemicals in fact filling in of data gaps In less time, money and experimental animals Promotion of tests which do not use experimental animals. Optimal use of in vitro tests Stimulation of development of new in vitro tests Minimalization of test strategies

3 RIP 3.3 drafting group RIP 3.3 team for genetic toxicology and carcinogenicity Craig Boreiko (ILZRO, USA) Håkan Cederberg (KEMI, Sweden), Chair Rafaella Corvi (ECVAM, Italy) Lena Hellmér (KEMI, Sweden) Dinant Kroese (TNO, The Netherlands) PMG representative Cyrille Krul (TNO, The Netherlands) Jay Niemela (DFVF, Denmark) Stefan Pfuhler (P&G, Switzerland) Robert Priston (SHELL, UK) Andrew Smith (HSE, UK) Jan van Benthem (RIVM, The Netherlands)

4 Changes in the new guidance documents Existing data should at all levels be considered Some new tests were introduced in the strategy Possibilities to waive tests For tests using vertebrate animals there is a need to make a proposal to the European Chemicals Agency first To ensure that the number of animals is kept to a minimum testing in one sex only may be sufficient Possibility to waive positive and negative controls in in vivo genotoxicity tests Incorporation of genotoxicity tests in other (toxicity tests)

5 REACH REACH strategy is tonnage triggered 1 10 tpa Annex VII tpa Annexes VII and VIII tpa Annex VII, VIII and IX > 1000 tpa Annex VII, VIII, IX and X Annex VII VIII IX X GM test in bacteria (Ames) CA test in mammalian cells in vitro GM test in mammalian cells in vitro CA test in mammalian cells in vivo GM test in mammalian cells in vivo Germ cell mutagenicity test Carcinogenicity

6 Evaluation of the results genotoxicity test Regarding positive test results: Responses only at highly toxic/cytotoxic concentrations should be interpreted with caution. The presence or absence of a dose-response relationship should be considered. Regarding negative test results: Were the concentrations of test substance used high enough? Was the test system used sensitive to the nature of the genotoxic changes that might have been expected? Was test substance volatile? Was, for studies in vitro, the metabolic activation system active in the system? Was the test substance taken up by the test organism used for in vitro studies? Was, for studies in vivo, the substance reaching the target organ?

7 Evaluation of genotoxicity test Regarding contradictory test results : Conflicting results between non-mammalian and mammalian cell tests. The results of mammalian tests may be considered of higher significance. The results of indicator tests not supported by results obtained in tests for mutagenicity. The results of mutagenicity tests are generally of higher significance. Contradictory findings obtained in vitro and in vivo. In general, the results of in vivo tests indicate a higher degree of reliability. Contradictory findings due to the sensitivity and specificity of different test systems. The result from the test system known to produce more accurate responses should be given higher priority. Intra or inter laboratory variability for the same test. In this case, expert judgement should be used to reach an overall evaluation of the data. Other considerations: The purity of the test substance. The quality of a study. In compliance with the requirements stated in the guideline and/or GLP.

8 Chemical Metabolic etoxicification Metabolic activation metabolites DNA DNA damage (= pre-mutagenic lesion) DNA repair metabolites irreversible DNA modifications (= mutations) Excretion gene mutations numerical chromosome aberrations structural chromosome aberrations GGAAGTCTA CGT TCAGAT 2n +1 GGAAATCTA CGT TTAGAT genetic disease cancer

9 Annex VII ( tpa) Standard information required Specific rules for adaptation In vitro gene mutation study in bacteria. Further mutagenicity studies shall be considered in case of a positive result.

10 REACH strategy (February 2007) REACH Annex VII gene mutation test in bacteria - + normally no further testing at this level proceed with Annex VIII

11 Annex VIII ( tpa) Standard information required Specific rules for adaptation In vitro gene cytogenetic study in mammalian cells. In vitro gene mutation study in mammalian cells, if a negative result in Ames test (Annex V and Annex VI). The study does not usually need to be conducted if:. adequate data from an in vivo cytogenicity study are available or. the substance is known to be carcinogenic category 1 or 2 or mutagenic category 1,2 or 3. Study does not usually need to be conducted if adequate data from a reliable in vivo mammalian gene mutation test are available, Appropriate in vivo mutagenicity studies shall be considered in case of a positive result in any of the mutagenicity studies in Annex VII or VIII.

12 REACH strategy (February 2007) REACH Annex VII gene mutation test in bacteria - + normally no further testing at this level proceed with Annex VIII REACH Annex VIII REACH Annex VII micronucleus test in vitro or chromosome aberration test in vitro + + proceed with Annex IX - mouse lymphoma assay (tk +/- locus) or hprt assay - no further testing not genotoxic

13 Accuracy of combinations of in vitro tests Ames + Ames + Ames + Ames + MN CA MN + CA + MLA MLA Sensitivity Specificity Concordance / /626 50/74 193/298 Positive predictivity Negative predictivity Ames: MLA: MN: CA: Ames test mouse lymphoma assay micronucleus test chromosome aberration test Kirkland et al, 2005

14 Annex IX ( tpa) Standard information required Specific rules for adaptation If there is a positive result in any of the in vitro genotoxicity studies in Annex VII or IX, and there are no results available from an in vivo study already, an appropriate in vivo somatic cell genotoxicity study shall be proposed by the registrant. If there is a positive result in an in vivo somatic cell study available, the potential for germ cell mutagenicity should be considered on the basis of all available data, including toxicokinetic evidence. If no clear conclusions about germ cell mutagenicity can be made, additional investigations shall be considered.

15 Annex X (> 1000 tpa) Standard information required Specific rules for adaptation If there is a positive result in any of the in vitro mutagenicity studies in Annex VII or IX, a second in vivo somatic cell test may be necessary, depending on the quality and relevance of all the available data. If there is a positive result in an in vivo somatic cell study available, the potential for germ cell mutagenicity should be considered on the basis of all available data, including toxicokinetic evidence. If no clear conclusions about germ cell mutagenicity can be made, additional investigations shall be considered.

16 REACH strategy (February 2007) REACH Annexes IX and X REACH Annex VIII consider whether in vivo test is required check bioavailability check available data consider proper in vivo (follow up) test consider integration into other toxicity tests Evidence of genotoxicity is an indicator of potential carcinogenicity - testing complete not genotoxic - 2 nd in vivo test + 1 st in vivo test - check available data check for information on a genotoxic hazard to germ cells +

17 Germ cell tests Are they superfluous?? Do tests performed in somatic cells cover the risk on mutations in germ cells?? Heritable translocation or specific locus test insensitive Dominant lethal test points to chromosomal aberrations To cover induction of gene mutations in germ cells non guideline tests have to be performed, e.g. gene mutation test with transgenic mice Different tests for both sexes? Different tests for different stages of oogenesis and spermatogenesis?

18 REACH in vivo testing positive Annex IX en X germ cell mutagenicity testing Requirements: Consider all available information: available genotoxicity data read across non testing data If sufficient information is available to conclude that the substance may pose a hazard to germ cells, it can be concluded that the substance may cause heritable genetic damage and no further testing is justified. - assess toxicokinetic/dynamic profile and apply expert judgement - undertake toxicokinetic study If this information is lacking or inconclusive germ cell tests are necessary. - avoid heritable translocation or specific locus test - non guideline tests may be alternatives

19 REACH Annexes IX and X REACH Annex VIII REACH strategy (February 2007) consider whether in vivo test is required check bioavailability check available data consider proper in vivo (follow up) test consider integration into other toxicity tests Evidence of genotoxicity is an indicator of potential carcinogenicity - testing complete not genotoxic - 2 nd in vivo test + 1 st in vivo test - check available data check for information on a genotoxic hazard to germ cells sufficient + insufficient testing complete genotoxic in somatic and germ cells + + sufficient - germ cell genotoxicity test - - testing complete genotoxic in somatic cells

20 Germ cell mutagenicity testing Is all available testing & non-testing data information sufficient to decide on germ cell mutagenicity insufficient sufficient - sufficient + Genotoxic cat 2 Genotoxic cat 3 or - Consider integration of germ cell test in toxicity test(s) still to be performed Decide for tests in germ cells per se or tests to detect damage in offspring Choose tests on endpoint specificity gene mutation test in Tg mice - + Genotoxic cat 3 or - clastogenicity in rodent spermatogonial cells dominant lethal test comet assay Expanded Simple Tandem Repeat (ESTR) + - Genotoxic cat 2 Genotoxic cat 3 or -

21 Annex X (> 1000 tpa) Standard information required Specific rules for adaptation Carcinogenicity study. A carcinogenicity study may be proposed by the registrant or may be required by the Agency in accordance with Articles 39 or 40 if. the substance has a widespread dispersive use or there is evidence of frequent or long term human exposure; and. the substance is classified as mutagen cat 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. If the substance is classified as mutagenic category 1 or 2, the default presumption would be that a genotoxic mechanism for carcinogenicity is likely. In these cases, a carcinogenicity test will normally not be required.

22 Carcinogenicity testing vs classification as mutagen Cat 1 or 2 mutagen: positive in in vivo genotoxicity tests. in somatic cells. in germ cells (tests or existing data) Cat 3 mutagen: positive in in vivo genotoxicity tests. in somatic cells (concern for man owing to the possibility that they may induce heritable mutations in germ cells of humans)

23 REACH strategy (February 2007) REACH Annex VII - IX Non testing data & Other relevant information Annex VII: in vitro genotoxicity data Annex VIII: in vitro and in vivo genotoxicity data subacute toxicity data Note: Carcinogenicity should be considered at every tonnage level Annex IX: in vitro and in vivo genotoxicity data (sub-) chronic toxicity data reprotoxicity data Based on all available testing & non-testing data regard as carcinogen if the compound: is considered carcinogenic from existing data is in vivo genotoxic induces hyperplasia and/or (pre-)neoplastic lesions in repeated dose toxicity studies

24 Is all available testing & non-testing data information sufficient to decide on both C&L and risk characterisation? no yes REACH Annex X Consider integration of carcinogenicity indicators in toxicity test(s) still to be performed If no option or not informative Go through steps of scheme II of GDMF; in case of need of further testing, consider: in vitro assays (e.g. for grouping confirmation, SHE etc), short term carcinogenicity assay (e.g. transgenic mice etc) Decide on yes or no carcinogenic and if carcinogenic Decide on dose descriptor to be used in risk characterisation Information sufficient to decide on both C&L and risk characterisation? no Consider the conduct of a classical 2-year carcinogenicity test yes Note: A carcinogenicity test should be considered as a last resort.

25 Classification and Labelling Classification and labelling of (genotoxic) carcinogens: On the basis of the results of the classical carcinogenicity tests and/or epidemiological data Problems may occur when a classical carcinogenicity test has been waived Considerations for compounds: positive in genotoxicity tests - carc cat 3 with indications for carcinogenicity from other (sub-)chronic toxicity tests - carc cat 3 positive in a in vitro transformation assay - carc cat 3 positive in a short term carcinogenicity assay with Tg mice - carc cat 2

26 Risk assessment Risk assessment of (genotoxic) carcinogens: On the basis of the results of the classical carcinogenicity tests and/or epidemiological data Derivation of a DMEL (derived minimal effect level) Problems may occur when a classical carcinogenicity test has been waived Suggestions in the guidance document: Read across/category approach Use of (sub-)chronic studies Use of the Threshold of Toxicity Concept Other suggestions not in the guidance document: Use of in silico methods (PBPK) ALARA principle Use of the Lowest Observed Effect Dose (LOED) of genotoxicity studies

27 Summary Under the REACH regulation it is possible to test chemicals for genotoxicity and carcinogenicity in an efficient manner without endangering the safety of the product use. Implementation of REACH will not hamper classification and labelling for genotoxicity and carcinogenicity as long as this is not exclusively permitted on data from germ cell genotoxicity tests or a classical carcinogenicity assay, respectively. REACH may be incomplete as risk assessment for genotoxic carcinogens. Special attention should be given to integrated (or intelligent) test systems (ITS) to accelerate evaluations of chemicals and reduce the number of tests. It is questionable whether under REACH the costs, number of tests and above all the number of laboratory animals for genotoxicity testing will actually be reduced. Since (sub-)chronic and carcinogenicity studies, non genotoxic carcinogens may go undetected very easily.

Genotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area

Genotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area Genotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area Juan Manuel Parra Morte. Pesticides Unit. EFSA. 19th Annual Conference of the

More information

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Official Journal of the European Union. (Non-legislative acts) REGULATIONS 21.2.2015 L 50/1 II (Non-legislative acts) REGULATIONS COMMISSION REGULATION (EU) 2015/282 of 20 February 2015 amending Annexes VIII, IX and X to Regulation (EC) No 1907/2006 of the European Parliament

More information

DISCUSSION GROUP 3. Mechanism of carcinogenicity. EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May

DISCUSSION GROUP 3. Mechanism of carcinogenicity. EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May DISCUSSION GROUP 3 Mechanism of carcinogenicity EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May 2008 1 1. Review the recent evidence for the mutagenicity and genotoxicity of acrylamide

More information

Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods

Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Guidance on Novel Foods From Animal Toxicity Studies to Safe Levels of Intake in Humans Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Info-session 06 March 2017 Parma

More information

VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing

VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing 6 November 2014 EMA/CVMP/VICH/526/2000 Committee for Medicinal Products for Veterinary Use (CVMP) VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing

More information

Comments CLH proposal Cadmium hydroxide

Comments CLH proposal Cadmium hydroxide 1 Comments CLH proposal Cadmium hydroxide GENERAL COMMENTS: The International Cadmium association (ICdA) welcomes the opportunity to provide its contribution to the public consultation on the proposed

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/43419 holds various files of this Leiden University dissertation. Author: Schaap, M.M. Title: The use of transcriptomics data in detecting non-genotoxic

More information

ANNEX IX STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 100 TONNES OR MORE ( 1 )

ANNEX IX STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 100 TONNES OR MORE ( 1 ) 29.5.2007 L 136/111 ANNEX IX REQUIREMTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 100 TONNES OR MORE ( 1 ) At the level of this Annex, the registrant must submit a proposal and a time schedule

More information

Lecture -2- Environmental Biotechnology

Lecture -2- Environmental Biotechnology Lecture -2-1-General Bioassay in pollution Monitoring 1 1 Genotoxicity test At the early testing stages, the genotoxicity assays for predicting potential heritable germ cell damage are the same as used

More information

Ecopa REACH Animal Use Calculator

Ecopa REACH Animal Use Calculator european consensus platform on 3R-alternatives Ecopa REACH Animal Use Calculator Karsten Müller & Simon Webb Apply the Same Principle as Today... Data Collection Classification, Labelling and SDS Risk

More information

Absorption, Distribution, Metabolism, Excretion and Toxicology

Absorption, Distribution, Metabolism, Excretion and Toxicology Draft Guidance Novel Foods Absorption, Distribution, Metabolism, Excretion and Toxicology Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Stakeholder Meeting, 11 April

More information

Evaluation & Reporting of Data: How to provide a (robust) study summary

Evaluation & Reporting of Data: How to provide a (robust) study summary Evaluation & Reporting of Data: How to provide a (robust) study summary Webinar on Information requirements 30 November 2009 Evaluation of all available information Step 1: Evaluation of the data quality

More information

ACRYLAMIDE - EU Summary of Activities

ACRYLAMIDE - EU Summary of Activities 6.1 In vivo DNA damaging effects of acrylamide in rats. France / French Food Safety Agency (AFSSA) C ( C December 2003 DNA damage of acrylamide in the main organs of rats will be studied using the in vivo

More information

Read-across illustrative example

Read-across illustrative example Part 2 Example 1 Analogue approach: similarity based on breakdown products Annankatu 18, P.O. Box 400, FI-00121 Helsinki, Finland Tel. +58 9 686180 Fax +58 9 68618210 echa.europa.eu 2 Example 1 DISCLAIMER

More information

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1 DRAFT opinion on genotoxicity testing strategies 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ENDORSED FOR PUBLIC CONSULTATION DRAFT SCIENTIFIC OPINION Scientific opinion

More information

Introduction to principles of toxicology and risk assessment

Introduction to principles of toxicology and risk assessment Introduction to principles of toxicology and risk assessment SEAC Training Helsinki, 29-30/06/2009 Kimmo Louekari Unit B4, Evaluation Disclaimer: This presentation does not represent ECHA s position on

More information

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1 EFSA Journal 2011;9(9):2379 SCIENTIFIC OPINION Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment 1 ABSTRACT EFSA Scientific Committee 2, 3 European Food

More information

Substance Evaluation Conclusion document EC No SUBSTANCE EVALUATION CONCLUSION DOCUMENT. as required by REACH Article 48.

Substance Evaluation Conclusion document EC No SUBSTANCE EVALUATION CONCLUSION DOCUMENT. as required by REACH Article 48. SUBSTANCE EVALUATION CONCLUSION DOCUMENT as required by REACH Article 48 for Butanone oxime EC No 202-496-6 CAS No 96-29-7 Evaluating Member State(s): Germany Dated: 18 March 2014 Evaluating Member State

More information

ENVIRONMENTAL REGULATIONS AND STANDARD SETTING Health Based Standards: Oncology - Luc Hens

ENVIRONMENTAL REGULATIONS AND STANDARD SETTING Health Based Standards: Oncology - Luc Hens HEALTH BASED STANDARDS: ONCOLOGY Luc Hens Human Ecology Department, Free University of Brussels (VUB), Belgium. Keywords: carcinogen, carcinogenesis, genotoxin, dose-response relationship, mutagen threshold,

More information

Annex II - List of enforceable provisions of REACH and CLP

Annex II - List of enforceable provisions of REACH and CLP Annex II - List of enforceable provisions of REACH and CLP The provisions below are listed according to the sections of the main report, together with the Titles of the Regulation in the case of REACH.

More information

The Comet Assay Tails of the (Un)expected

The Comet Assay Tails of the (Un)expected The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic

More information

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology TECHNICAL REPORT APPROVED: 25 July 2016 Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology Abstract European Food Safety Authority This technical report reflects

More information

Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1

Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1 Maria João Silva H. Louro 1, T. Borges 2, J. Lavinha 1, J.M. Albuquerque 1 1 National Institute of Health Dr. Ricardo Jorge 2 General-Directorate of Health, Lisbon, Portugal Venice.,10-03-2015 The number

More information

Official Journal of the European Union

Official Journal of the European Union 1.6.2016 L 144/27 COMMISSION REGULATION (EU) 2016/863 of 31 May 2016 amending Annexes VII and VIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation,

More information

Step by Step Approach for GPS Risk Assessment

Step by Step Approach for GPS Risk Assessment Step by Step Approach for GPS Risk Assessment 1) Tier Categorization and Prioritization 2) Hazard Characterization By Mr. Krittanon Yuen-ying (Product Regulatory) Dow Chemical Thailand Limited Email: krittanon.yuen-ying@dow.com

More information

DRAFT for public consultation. Reflection on interpretation of some aspects related to genotoxicity assessment. EFSA Scientific Committee:

DRAFT for public consultation. Reflection on interpretation of some aspects related to genotoxicity assessment. EFSA Scientific Committee: SCIENTIFIC OPINION ADOPTED: doi:10.2903/j.efsa.20yy.nnnn 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 DRAFT for public consultation Reflection

More information

Test guidelines and guidance documents in the field of plant protection products

Test guidelines and guidance documents in the field of plant protection products Test guidelines and guidance documents in the field of plant protection products BfR background information No. 032/2015 of 3 August 2015 The legislator has stipulated binding rules determining which test

More information

Developmental neurotoxicity & REACH

Developmental neurotoxicity & REACH Developmental neurotoxicity & REACH Hannele Huuskonen DNT WS 2016 REACH Article 1 The purpose of this Regulation is to ensure a high level of protection of human health and the environment, including the

More information

Opinion of the Scientific Committee on Food on an additional list of monomers and additives for food contact materials (adopted the 18 September 1998)

Opinion of the Scientific Committee on Food on an additional list of monomers and additives for food contact materials (adopted the 18 September 1998) Opinion of the Scientific Committee on Food on an additional list of monomers and additives for food contact materials (adopted the 18 September 1998) The Committee (re)evaluated a number of monomers and

More information

Justification for the selection of a candidate CoRAP substance

Justification for the selection of a candidate CoRAP substance Justification for the selection of a candidate CoRAP substance Substance Name (Public Name): Chemical Group: N,N-dicyclohexylbenzothiazole-2-sulphenamide Benzothiazole EC Number: 225-625-8 CAS Number:

More information

3-MCPD and glycidol and their esters

3-MCPD and glycidol and their esters Toxicological Risk Assessment of 3-monochloropropane-1,2-diol (3-MCPD) Esters and Glycidol Esters: Is there a Need for Concern? Ivonne M.C.M. Rietjens Division of Toxicology Wageningen University ivonne.rietjens@wur.nl

More information

RISK MANAGEMENT OPTION ANALYSIS CONCLUSION DOCUMENT

RISK MANAGEMENT OPTION ANALYSIS CONCLUSION DOCUMENT RISK MANAGEMENT OPTION ANALYSIS CONCLUSION DOCUMENT for Substance name: 2,4,6-trimethyl-2,4,6-tris(3,3,3- trifluoropropyl)cyclotrisiloxane, F-D3 EC number: 219-154-7 CAS number: 2374-14-3 Member State(s):

More information

Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Health and environmental hazards Classification criteria for substances and mixtures Working definitions Substance: Chemical

More information

Survey results - Analysis of higher tier studies submitted without testing proposals

Survey results - Analysis of higher tier studies submitted without testing proposals Survey results - Analysis of higher tier studies submitted without testing proposals Submission of higher tier studies on vertebrate animals for REACH registration without a regulatory decision on testing

More information

5.36 THIOPHANATE-METHYL (077)

5.36 THIOPHANATE-METHYL (077) 391 5.36 THIOPHANATE-METHYL (077) TOXICOLOGY is the International Organization for Standardization (ISO) approved common name for dimethyl 4,4 -(o-phenylene)bis(3-thioallophanate) (International Union

More information

Genotoxicity of formaldehyde in vitro and in vivo. Günter Speit

Genotoxicity of formaldehyde in vitro and in vivo. Günter Speit Genotoxicity of formaldehyde in vitro and in vivo Günter Speit Universität Ulm Institut für Humangenetik D-89069 Ulm (Germany) guenter.speit@uni-ulm.de CEFIC-2012 Günter Speit 1 Genotoxicity of formaldehyde

More information

Section 5.3: Preclinical safety data

Section 5.3: Preclinical safety data Section 5.3: Preclinical safety data SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group

More information

MIE KE2 AO Mutations per LacZ mutant. [van Delft and Baan 1995] [O'Brien et al. 2014]

MIE KE2 AO Mutations per LacZ mutant. [van Delft and Baan 1995] [O'Brien et al. 2014] Table I. Empirical data for male rodents exposed to germ cells for ENU. Dose (mg/kg) a Alkyl Adducts per nucleotide in male germ cells b MIE KE2 AO Mutations per LacZ mutant nucleotide in Time of frequency

More information

MANGANESE & HEALTH: A BALANCE OF STORIES

MANGANESE & HEALTH: A BALANCE OF STORIES MANGANESE & HEALTH: A BALANCE OF STORIES November 2014 1 Overview 2. Analysis of Literature on Carcinogenicity & Mutagenicity 1. Uses of inorganic Mn substances 3. Research to better understand Carcinogenicity

More information

LOW DOSES OF RADIATION REDUCE RISK IN VIVO

LOW DOSES OF RADIATION REDUCE RISK IN VIVO Dose-Response: An International Journal Volume 5 Issue 1 ADAPTIVE BIOLOGICAL RESPONSES FOLLOWING EXPOSURES TO IONIZING RADIATION Article 4 3-2007 LOW DOSES OF RADIATION REDUCE RISK IN VIVO REJ Mitchel

More information

Criteria for toxicological characterization metabolites and testing strategy

Criteria for toxicological characterization metabolites and testing strategy Criteria for toxicological characterization of metabolites and testing strategy Parma, 26 and 27 September 2016, Infosession Andrea Terron EFSA, Pesticide Unit UTLINE Identification of metabolites characterised

More information

Guidance on information requirements and Chemical Safety Assessment. Chapter R.7a: Endpoint specific guidance

Guidance on information requirements and Chemical Safety Assessment. Chapter R.7a: Endpoint specific guidance DRAFT Chapter R.a: Endpoint specific guidance PUBLIC: Draft Version x.0 xxxx 0 G U I D A N C E Guidance on information requirements and Chemical Safety Assessment Chapter R.a: Endpoint specific guidance

More information

EFSA working group on BPA assessment protocol. Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol

EFSA working group on BPA assessment protocol. Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol EFSA working group on BPA assessment protocol Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol Workshop on BPA hazard assessment protocol Brussels, 14 September 2017 Acknowledgements

More information

1 OJ L 354, , p OJ L 80, , p. 19.

1 OJ L 354, , p OJ L 80, , p. 19. Call for scientific and technical data on the permitted food additives E 140(i) chlorophylls, E 140(ii) chlorophyllins, E 141(i) copper complexes of chlorophylls and E 141(ii) copper complexes of chlorophyllins

More information

International Safety Assessment of Sweeteners

International Safety Assessment of Sweeteners ILSI SEA Region Seminar on Uses and Safety of Sweeteners (May 2013) http://www.ilsi.org/sea_region/pages/vieweventdetails.aspx?webid=4d540914-eeb6-40e4-89eb- 0B73BA3D76C1&ListId=478BE3CB-581B-4BA2-A280-8E00CCB26F9C&ItemID=73

More information

Nonclinical Safety Evaluation of Inhalation Drug Products

Nonclinical Safety Evaluation of Inhalation Drug Products Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center

More information

TNsG on Annex I Inclusion Revision of Chapter 4.1: Quantitative Human Health Risk Characterisation

TNsG on Annex I Inclusion Revision of Chapter 4.1: Quantitative Human Health Risk Characterisation TNsG on Annex I Inclusion Revision of Chapter 4.1: Quantitative Human Health Risk Characterisation These Technical Notes for Guidance were adopted during the 34 th meeting of representatives of Members

More information

Glyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies

Glyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies Glyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies David A. Eastmond Environmental Toxicology Graduate Program University of California, Riverside Glyphosate

More information

ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals. Step 5

ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals. Step 5 European Medicines Agency March 1998 CPMP/ICH/299/95 ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON CARCINOGENICITY: TESTING FOR CARCINOGENICITY

More information

Justification for the selection of a candidate CoRAP substance UPDATE

Justification for the selection of a candidate CoRAP substance UPDATE Justification for the selection of a candidate CoRAP substance UPDATE Substance Name (Public Name): Chemical Group: Tetrapropylenebenzene Branched alkylbenzenes EC Number: 246-772-4 CAS Number: 25265-78-5

More information

New Technologies for Predicting Genotoxic Risk in Humans

New Technologies for Predicting Genotoxic Risk in Humans New Technologies for Predicting Genotoxic Risk in Humans 2010 HESI Annual Meeting May 12, 2010 David Jacobson-Kram, Ph.D., DABT Office of New Drugs, CDER, FDA Role of genetic toxicology testing Genetic

More information

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP)

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP) 1 (10) Helsinki, 09 September 2016 RAC/38/2016/09 rev 1 Final APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP) Background At the 22 nd meeting of the Committee for

More information

Part 2. Chemical and physical aspects

Part 2. Chemical and physical aspects Part 2. Chemical and physical aspects 12. Chemical and physical aspects: introduction 12.1 Background information used The assessment of the toxicity of drinking-water contaminants has been made on the

More information

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date

More information

WP 6 In vivo genotoxicity

WP 6 In vivo genotoxicity WP 6 In vivo genotoxicity Valérie Fessard Anses Fougères France valerie.fessard@anses.fr NANOGENOTOX Final conference 22 February 2013 WP6 partners 9 partners from 7 countries Aims Determine the in vivo

More information

ECPA position paper on the criteria for the determination of endocrine disrupting properties under Regulation

ECPA position paper on the criteria for the determination of endocrine disrupting properties under Regulation POSITION PAPER 09/06/2016 PP/14/PD/23734 ECPA position paper on the criteria for the determination of endocrine disrupting properties under Regulation The European Commission is currently developing new

More information

Committee for Risk Assessment RAC

Committee for Risk Assessment RAC ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPSAL ON FUBERIDAZOLE Committee for Risk Assessment RAC Annex 2 Response to comments document (RCOM) to the Opinion proposing harmonised classification

More information

Ian Indans Regulatory scientist Chemicals Regulation Directorate (CRD)

Ian Indans Regulatory scientist Chemicals Regulation Directorate (CRD) Health and Safety Executive Ian Indans Regulatory scientist Chemicals Regulation Directorate (CRD) Health and Safety Executive Acute Inhalation Toxicity testing; The 3Rs, Current needs and Future Prospects

More information

Genetic Toxicology. Toxicology for Industrial and Regulatory Scientists

Genetic Toxicology. Toxicology for Industrial and Regulatory Scientists Toxicology for Industrial and Regulatory Scientists Genetic Toxicology Mark W. Powley, Ph.D. Pharmacology/Toxicology Reviewer Division of Antiviral Products FDA/CDER/OND April 29, 2015 1 Outline Background

More information

Committee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of. acetaldehyde; ethanal

Committee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of. acetaldehyde; ethanal Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of acetaldehyde; ethanal EC Number: 200-836-8 CAS Number: 75-07-0 CLH-O-0000001412-86-120/F Adopted

More information

Dossier Quality Assistant

Dossier Quality Assistant Overview of DQA rules 6 March 2014 Dossier Quality Assistant This document gives an overview of the rules covered by the Dossier Quality Assistant (DQA), which is incorporated in the IUCLID Validation

More information

COMMISSION REGULATION (EU) / of XXX

COMMISSION REGULATION (EU) / of XXX Ref. Ares(2017)4140854-23/08/2017 EUROPEAN COMMISSION Brussels, XXX SANTE/10578/2017 Rev. 2 CIS (POOL/E2/2017/10578/10578R2-EN CIS.doc) [ ](2017) XXX draft COMMISSION REGULATION (EU) / of XXX on the use

More information

Genotoxicity of 2-Hydroxy-1,4-naphthoquinone (Lawsone, CAS )

Genotoxicity of 2-Hydroxy-1,4-naphthoquinone (Lawsone, CAS ) Genotoxicity of 2-Hydroxy-1,4-naphthoquinone (Lawsone, CAS 83-72-7) Bewertung des BgVV vom 21. Juni 2002 Die Substanz Lawson (2-Hydroxy-1,4-naphthochinon) ist ein Bestandteil von Haarfärbemitteln wie z.b.

More information

1,1 - iminodipropan-2-ol

1,1 - iminodipropan-2-ol Possibility for MSCA Logo] SUBSTANCE EVALUATION CONCLUSION DOCUMENT as required by REACH Article 48 for 1,1 - iminodipropan-2-ol EC No 203-820-9 CAS No 110-97-4 Evaluating Member State(s): Czech Republic

More information

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements OECD QSAR Toolbox v.4.2 An example illustrating RAAF scenario 6 and related assessment elements Outlook Background Objectives Specific Aims Read Across Assessment Framework (RAAF) The exercise Workflow

More information

Explanatory note. On an opinion proposing harmonised classification and labelling at EU level of. glyphosate (ISO); N-(phosphonomethyl)glycine

Explanatory note. On an opinion proposing harmonised classification and labelling at EU level of. glyphosate (ISO); N-(phosphonomethyl)glycine Explanatory note On an opinion proposing harmonised classification and labelling at EU level of glyphosate (ISO); N-(phosphonomethyl)glycine EC Number: 213-997-4 CAS Number: 1071-83-6 This note has been

More information

Human Health Classification: General Considerations and Overview

Human Health Classification: General Considerations and Overview Human Health Classification: General Considerations and Overview 1 Key considerations for GHS Classifications Focuses on Self Classification by industry Identify Physical State e.g., metal salt, oxide,

More information

Reproductive toxicity classification under CLP (Regulation (EC) no 1272/2008 on Classification, Labelling and Packaging of chemicals)

Reproductive toxicity classification under CLP (Regulation (EC) no 1272/2008 on Classification, Labelling and Packaging of chemicals) Reproductive toxicity classification under CLP (Regulation (EC) no 1272/2008 on Classification, Labelling and Packaging of chemicals) A satellite workshop to the 45th Annual Meeting of the European Teratology

More information

Justification Document for the Selection of a CoRAP Substance

Justification Document for the Selection of a CoRAP Substance Justification Document for the Selection of a CoRAP Substance Substance Name (public name): Sodium hydroxymethanesulphinate EC Number: 205-739-4 CAS Number: 149-44-0 Authority: NL MSCA Date: 22/03/2016

More information

- draft scientific opinion -

- draft scientific opinion - The Re-evaluation of faspartame - draft scientific opinion - Dr. Alicja Mortensen Chair of EFSA s ANS Panel Follow-up meeting on the web-based public consultation on aspartame 9 April 2013, Bruxelles Draft

More information

Risk Assessment Report on Vinyl acetate. Human Health Part. CAS No.: EINECS No.:

Risk Assessment Report on Vinyl acetate. Human Health Part. CAS No.: EINECS No.: Scientific Committee on Health and Environmental Risks SCHER Risk Assessment Report on Vinyl acetate Human Health Part CAS No.: 108-05-4 EINECS No.: 203-545-4 The SCHER adopted this opinion at its 26 th

More information

Regulation of Genotoxic and Carcinogenic Impurities in

Regulation of Genotoxic and Carcinogenic Impurities in Regulation of Genotoxic and Carcinogenic Impurities in Pharmaceuticals Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT

More information

Annex II. Scientific conclusions and grounds for variation to the terms of the marketing authorisations

Annex II. Scientific conclusions and grounds for variation to the terms of the marketing authorisations Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations 13 Scientific conclusions Overall summary of the scientific evaluation of thiocolchicoside containing

More information

Feedback from the Member States questionnaire

Feedback from the Member States questionnaire Annex 6 Feedback from the Member States questionnaire Reinhilde A.R. Schoonjans Special meeting of the EFSA Advisory Forum on GMO risk assessment in Europe 13 November 2007, Brussels Topics 1. Highlights

More information

Risk Assessment Report on Tris (nonylphenyl)phosphite (TNPP)

Risk Assessment Report on Tris (nonylphenyl)phosphite (TNPP) EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON HEALTH AND ENVIRONMENTAL RISKS SCHER

More information

Risk Assessment Report on styrene. Human Health Part

Risk Assessment Report on styrene. Human Health Part Scientific Committee on Health and Environmental Risks SCHER Risk Assessment Report on styrene Human Health Part CAS No.: 100-42-6 EINECS no.: 202-851-5 SCHER adopted this opinion at its 23 rd plenary

More information

ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate

ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate Tim Bowmer, Committee Chairman Ari Karjalainen, Dossier Manager for Glyphosate 10 May 2017 1 Established

More information

COMMISSION REGULATION (EU) / of XXX

COMMISSION REGULATION (EU) / of XXX Ref. Ares(2017)4140854-23/08/2017 EUROPEAN COMMISSION Brussels, XXX SANTE/10578/2017 Rev. 2 CIS (POOL/E2/2017/10578/10578R2-EN CIS.doc) [ ](2017) XXX draft COMMISSION REGULATION (EU) / of XXX on the use

More information

Trisodium nitrilotriacetate (NTA)

Trisodium nitrilotriacetate (NTA) RISK MANAGEMENT OPTIONS ANALYSIS CONCLUSION DOCUMENT for Trisodium nitrilotriacetate (NTA) EC No 225-768-6 CAS No 5064-31-3 Member State: Denmark Dated: August 2014, Final version Disclaimer: Please note

More information

Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request related to

Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request related to The EFSA Journal (2006) 316 to 318, 1-10 Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request related to an 11 th list of

More information

Committee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of. cobalt

Committee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of. cobalt Committee for Risk Assessment RAC Opinion proposing harmonised classification and labelling at EU level of cobalt EC Number: 231-158-0 CAS Number: 7440-48-4 CLH-O-0000001412-86-172/F Adopted 22 September

More information

Optimal Design for in Vivo Mutation Studies to Inform Cancer Mode-of- Action Assessment

Optimal Design for in Vivo Mutation Studies to Inform Cancer Mode-of- Action Assessment Optimal Design for in Vivo Mutation Studies to Inform Cancer Mode-of- Action Assessment Martha M. Moore, Ph.D. Director, Division of Genetic and Reproductive Toxicology National Center for Toxicological

More information

General Hazard Profile of Pigments

General Hazard Profile of Pigments General Hazard Profile of Pigments First International Conference on Tattoo Safety Berlin, June 6 and 7, 2013 Dr. W. Teubner, EUROTOX-registered toxicologist Product Safety Switzerland A note at the beginning

More information

Received: 20 March 2014, Revised: 11 June 2014, Accepted: 11 June 2014 Published online in Wiley Online Library: 25 July 2014

Received: 20 March 2014, Revised: 11 June 2014, Accepted: 11 June 2014 Published online in Wiley Online Library: 25 July 2014 Review Hypothesis Received: 20 March 2014, Revised: 11 June 2014, Accepted: 11 June 2014 Published online in Wiley Online Library: 25 July 2014 (wileyonlinelibrary.com) DOI 10.1002/jat.3045 A proposal

More information

COMMISSION REGULATION (EU)

COMMISSION REGULATION (EU) 11.3.2011 Official Journal of the European Union L 64/15 COMMISSION REGULATION (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council

More information

Dose response relationships: biological and modeling aspects

Dose response relationships: biological and modeling aspects Dose response relationships: biological and modeling aspects Jason Aungst, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration The findings

More information

ToxStrategies, Inc. and Summit Toxicology

ToxStrategies, Inc. and Summit Toxicology Deborah Proctor Chad Thompson, Mark Harris, Mina Suh, Laurie Haws, Chris Kirman and Sean Hays ToxStrategies, Inc. and Summit Toxicology November 2012 Research Project funded by the Cr 6 Panel of the American

More information

Methodologies for development of human health criteria and values for the lake Erie drainage basin.

Methodologies for development of human health criteria and values for the lake Erie drainage basin. 3745-1-42 Methodologies for development of human health criteria and values for the lake Erie drainage basin. [Comment: For dates of non-regulatory government publications, publications of recognized organizations

More information

BENZETHONIUM CHLORIDE

BENZETHONIUM CHLORIDE OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING BENZETHONIUM CHLORIDE COLIPA n P 70 adopted by the SCCNFP during the 26 th plenary meeting

More information

SCIENTIFIC OPINION. EFSA Panel on food contact materials, enzymes, flavourings and processing aids (CEF) 2, 3

SCIENTIFIC OPINION. EFSA Panel on food contact materials, enzymes, flavourings and processing aids (CEF) 2, 3 EFSA Journal 2012;10(7):2825 SCIENTIFIC OPINION Scientific Opinion on the safety evaluation of the substance, 2-phenyl-3,3-bis(4-hydroxyphenyl)phthalimidine, CAS No. 6607-41-6, for use in food contact

More information

This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium

This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium Date: 10/12/2013 RE: ECHA Consultation period 29/10/2013 to 13/12/2013 on Harmonised Classification

More information

European Food Safety Authority (EFSA)

European Food Safety Authority (EFSA) STATEMENT ADOPTED: 5 July 2018 doi: 10.2903/j.efsa.2018.5383 Statement on the impact of the harmonised classification on the conclusion on the peer review of the pesticide risk assessment of the active

More information

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017

The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017 The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats. Status Report December 2017 Jan Willem van der Laan ( EC, Europe, Regulatory Chair), Todd Bourcier (FDA, US), Tania Cavaliero (Swissmedic,

More information

Justification for the selection of a substance for CoRAP inclusion

Justification for the selection of a substance for CoRAP inclusion Justification for the selection of a substance for CoRAP inclusion Substance Name (Public Name): Chemical Group: Aluminium chloride inorganic mono constituent substance EC Number: 231-208-1 CAS Number:

More information

ASSESSING ENDOCRINE DISRUPTING SUBSTANCES

ASSESSING ENDOCRINE DISRUPTING SUBSTANCES FEDERAL INSTITUTE FOR RISK ASSESSMENT ASSESSING ENDOCRINE DISRUPTING SUBSTANCES Handling of risk assessment under different regulations Andreas Hensel How EDs may act - sexual hormones as an example Hypothalamus

More information

Research Framework for Evaluating the Potential Mode(s)

Research Framework for Evaluating the Potential Mode(s) Research Framework for Evaluating the Potential Mode(s) of Action Underlying the Carcinogenicity of Hexavalent Chromium Following Exposure in Drinking Water Developed by Staff and Management at the The

More information

Webinar: use of alternative methods to animal testing in your REACH registration

Webinar: use of alternative methods to animal testing in your REACH registration Webinar: use of alternative methods to animal testing in your REACH registration Using alternative methods to meet your information requirements 22 September 2016 Kimmo Louekari Evaluation Unit European

More information

BEIR VIII Planning Meeting

BEIR VIII Planning Meeting BEIR VIII Planning Meeting Recent reviews and novel data - low dose radiobiology Simon Bouffler 17 November 2014 Outline Advisory Group on Ionising Radiation activities human radiosensitivity, transgenerational

More information

Alternative approaches to standard toxicity testing

Alternative approaches to standard toxicity testing OR 71/2011 Alternative approaches to standard toxicity testing TQP ID 9 OPTION 257430181 NILU Mikael Harju, Solveig Ravnum, Elise Rundén Pran, Sonja Grossberndt, Lise Marie Fjellsbø, Maria Dusinska and

More information

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT

More information